Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cariporide SCHEMBL611696 | 0.84 | SLC9A1 (1.00) | SLC9A1SLC9A2 | |
| Cariporide SCHEMBL31563713 | 0.81 | SLC9A1 (1.00) | SLC9A1SLC9A2 | |
| Cariporide SCHEMBL1648723 | 0.81 | SLC9A1 (1.00) | SLC9A1SLC9A2 | |
| SCHEMBL4355373 | 0.81 | SLC9A1 (0.72) | SLC9A1SLC9A2 | |
| Cariporide SCHEMBL8743795 | 0.80 | SLC9A1 (0.97) | SLC9A1SLC9A2 | |
| SCHEMBL7061450 | 0.78 | SLC9A1 (0.71) | SLC9A1SLC9A2 | |
| SCHEMBL18929891 | 0.74 | SLC9A1 (0.71) | SLC9A1SLC9A2 | |
| SCHEMBL8743809 | 0.72 | SLC9A1 (0.76) | SLC9A1SLC9A2 | |
| Hydrochloric Acid SCHEMBL8743818 | 0.71 | SLC9A1 (0.74) | SLC9A1SLC9A2 | |
| Cariporide SCHEMBL221094 | 0.71 | SLC9A1 (0.63) | SLC9A1SLC9A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040044081-A1 | Diacyl-substituted guanidines, a process for their preparation, their use as medicament or diagnostic aid, and medicament containing them | HOECHST AKTIENGESELLSCHAFT | 2004-03-04 | — | — | US | disclosed |
| US-6632840-B1 | Inhibiting the Na+/H+ exchanger, treating at least one of arrhythmias and shock | HOECHST AKTIENGESELLSCHAFT (DE) | 2003-10-14 | — | — | US | disclosed |
| US-6436999-B1 | REACTING GUANIDINE AND CARBOCYCLIC ACIDS, TO FORM COMPOUNDS LIKE BIS(3-METHYLSULFONYL-4-I-PROPYLBENZOYL)GUANIDINE, USED FOR PROPHYLAXIS OF CARDIOVASCULAR DISORDERS AND AS PRODRUGS FOR SODIUM CHANNEL MODULATORS TO CONTROL BLOOD PRESSURE | HOECHST AKTIENGESELLSCHAFT (DE) | 2002-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040044081-A1 | Diacyl-substituted guanidines, a process for their preparation, their use as medicament or diagnostic aid, and medicament containing them | ADRA1B, ADRA1A, HYOU1 | SLC9A1 37/4885SLC9A2 112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.